Javascript must be enabled to continue!
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
View through CrossRef
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has been shown to interact with the cAMP response element (CRE) site present in many cis-elements of downstream target genes. JDP2 has also demonstrates important roles in cell-cycle regulation, cancer development and progression, inhibition of adipocyte differentiation, and the regulation of antibacterial immunity and bone homeostasis. JDP2 and ATF3 exhibit significant similarity in their C-terminal domains, sharing 60–65% identities. Previous studies have demonstrated that ATF3 is able to influence both the transcriptional activity and p53 stability via a p53-ATF3 interaction. While some studies have shown that JDP2 suppresses p53 transcriptional activity and in turn, p53 represses JDP2 promoter activity, the direct interaction between JDP2 and p53 and the regulatory role of JDP2 in p53 transactivation have not been explored. In the current study, we provide evidence, for the first time, that JDP2 interacts with p53 and regulates p53 transactivation. First, we demonstrated that JDP2 binds to p53 and the C-terminal domain of JDP2 is crucial for the interaction. Second, in p53-null H1299 cells, JDP2 shows a robust increase of p53 transactivation in the presence of p53 using p53 (14X)RE-Luc. Furthermore, JDP2 and ATF3 together additively enhance p53 transactivation in the presence of p53. While JDP2 can increase p53 transactivation in the presence of WT p53, JDP2 fails to enhance transactivation of hotspot mutant p53. Moreover, in CHX chase experiments, we showed that JDP2 slightly enhances p53 stability. Finally, our findings indicate that JDP2 has the ability to reverse MDM2-induced p53 repression, likely due to decreased levels of MDM2 by JDP2. In summary, our results provide evidence that JDP2 directly interacts with p53 and decreases MDM2 levels to enhance p53 transactivation, suggesting that JDP2 is a novel regulator of p53 and MDM2.
Title: Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Description:
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families.
JDP2 has been shown to interact with the cAMP response element (CRE) site present in many cis-elements of downstream target genes.
JDP2 has also demonstrates important roles in cell-cycle regulation, cancer development and progression, inhibition of adipocyte differentiation, and the regulation of antibacterial immunity and bone homeostasis.
JDP2 and ATF3 exhibit significant similarity in their C-terminal domains, sharing 60–65% identities.
Previous studies have demonstrated that ATF3 is able to influence both the transcriptional activity and p53 stability via a p53-ATF3 interaction.
While some studies have shown that JDP2 suppresses p53 transcriptional activity and in turn, p53 represses JDP2 promoter activity, the direct interaction between JDP2 and p53 and the regulatory role of JDP2 in p53 transactivation have not been explored.
In the current study, we provide evidence, for the first time, that JDP2 interacts with p53 and regulates p53 transactivation.
First, we demonstrated that JDP2 binds to p53 and the C-terminal domain of JDP2 is crucial for the interaction.
Second, in p53-null H1299 cells, JDP2 shows a robust increase of p53 transactivation in the presence of p53 using p53 (14X)RE-Luc.
Furthermore, JDP2 and ATF3 together additively enhance p53 transactivation in the presence of p53.
While JDP2 can increase p53 transactivation in the presence of WT p53, JDP2 fails to enhance transactivation of hotspot mutant p53.
Moreover, in CHX chase experiments, we showed that JDP2 slightly enhances p53 stability.
Finally, our findings indicate that JDP2 has the ability to reverse MDM2-induced p53 repression, likely due to decreased levels of MDM2 by JDP2.
In summary, our results provide evidence that JDP2 directly interacts with p53 and decreases MDM2 levels to enhance p53 transactivation, suggesting that JDP2 is a novel regulator of p53 and MDM2.
Related Results
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract 1176: Bypassing the dominant-negative effect of mutant p53 in cancer cells
Abstract
The tumor suppressor p53 is mutated in more than 50% of all cancers. The transcriptional activity of p53 depends on localization to the nucleus and formatio...
Abstract 1234: Impact of cancer-associated mutations on MDM2 function
Abstract 1234: Impact of cancer-associated mutations on MDM2 function
Abstract
MDM2 is an E3 ubiquitin ligase that functions as a negative regulator of the tumor suppressor p53. MDM2 can promote the ubiquitination and proteasomal degra...
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Abstract 829: p53 dimers elicit tumor suppressive activities through an altered metabolic program
Abstract 829: p53 dimers elicit tumor suppressive activities through an altered metabolic program
Abstract
p53 is the most frequently mutated gene in human cancer. As a tetrameric transcription factor, mutation of the p53 Tetramerization Domain (TD) is a mechanis...
Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
Overexpression of the oncoprotein MDM2, an important regulator of the p53 tumor suppressor protein, is often observed in breast cancer tissues and cell lines, particularly in those...
Abstract 1645: Discovery of AMG 232, an inhibitor of the MDM2-p53 interaction: From lead to a clinical candidate
Abstract 1645: Discovery of AMG 232, an inhibitor of the MDM2-p53 interaction: From lead to a clinical candidate
Abstract
The p53 tumor suppressor is controlled by MDM2, which binds p53 and negatively regulates its transcriptional activity and stability. Many tumors overproduce...
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
Inhibition of the MDM2/X-p53 interaction is recognized as a potential anti-cancer strategy, including the treatment of glioblastoma (GB). In response to cellular stressors, such as...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...

